Article 1:

Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies
Yuan J, et al. Gut 2021;70:1070–1077

DOI: 10.1136/gutjnl-2020-322557
PDF: Yuan et al PPI type 2 DM Gut 2021.full

Summary:

PPI use has been associated with a number of medical conditions, including C diff infection, community-acquired pneumonia, and bone density loss. The authors combined 3 large prospective cohorts (Nurses’ Health Study I and II and Health Professionals Follow up  Study) and found that regular PPI users had a higher risk of incident diabetes (HR 1.24, 95% CI 1.17-1.31), with the risk associated with duration of PPI use. The authors propose that changes in the gut microbiome could be responsible for this effect.

Fellow Presenter: Kara Wegermann
Faculty Preceptor: Rick Wood

Article 2:

Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Q1 Case-Control Study
J Clin Invest. 2021;131(3):e143301

DOI: doi.org/10.1016/j.cgh.2021.05.038
PDF: Berinstein et al. Tofacitinib for Severe UC in Hospitalize Biologic-Experienced Pts

Summary:

Tofacitinib, a Janus kinase inhibitor, has proven efficacy in treating ulcerative colitis and may provide additional means for preventing colectomy in patients with acute severe ulcerative colitis. This study is a retrospective case-control study performed to evaluate the efficacy of tofacitinib induction in biologic-experienced patients with acute severe ulcerative colitis and demonstrates that tofacitinib in conjunction with IV steroids may be an effective induction strategy in this patient population.

Fellow Presenter: Talisha Ramchal
Faculty Preceptor: CeCe Zhang